At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 82 enrolled
Drug / intervention
Lenvatinibdrug
Likely dose
Lenvatinib tablets taken orally, once daily (dose to be escalated; specific starting dose not stated)AI-extracted
Key inclusion· 4
- ✓Histologically and/or cytologically confirmed solid tumor or lymphoma resistant/refractory to approved therapies or for whom no appropriate therapies are available
- ✓Age ≥18 years
- ✓Karnofsky performance status ≥70%
- ✓All previous treatment (including surgery and radiotherapy) completed at least 4 weeks prior to study entry with resolved acute toxicities
Key exclusion· 8
- ✕Brain tumors or brain or leptomeningeal metastases
- ✕Centrally located or squamous cell carcinoma of the lung
- ✕Uncontrolled infections
- ✕Clinically significant cardiac impairment or unstable ischemic heart disease including myocardial infarction within 6 months
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open Label Phase I Dose Escalation Study Of E7080
In Brief
A Phase 1 clinical trial evaluating Lenvatinib for Solid Tumor or Lymphoma. Completed, enrolled 82 participants across 2 sites in 2 countries.
Detailed Summary
The purpose of this study is to determine the maximum tolerated dose (MTD) of lenvatinib in patients with solid tumors or lymphomas.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSolid Tumor or Lymphoma
CountriesNetherlands, United Kingdom
Collaborators--
Timeline
Phase 1CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJul 2005
First PostedJul 2005
Primary CompletionJun 2009
Study CompletionMar 2019
TodayJul 2026
First PostedJul 21, 2005
Enrollment StartJul 1, 2005
Primary CompletionJun 19, 2009
Study CompletionMar 1, 2019
TodayJul 2, 2026
Enrollment to primary: 4.0 yearsPosted 20.9 years ago
Interventions
Lenvatinibdrug
Lenvatinib tablets taken orally, once daily.